Aardvark Therapeutics announced that the FDA has imposed a full clinical hold on its ARD-101 investigational new drug application, affecting all ongoing studies including the Phase 3 HERO and open-label extension trials for treating hyperphagia in Prader-Willi Syndrome patients. The company is working closely with the FDA to resolve the hold and plans to unblind existing trial data to evaluate safety and efficacy before deciding the next steps. Aardvark has sufficient cash reserves to fund operations into mid-2027 and remains committed to advancing ARD-101 as a potential therapy for this rare condition.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
